Sydney, Sep 11, 2017 - (ABN Newswire) - The following investment report by Edison titled ‘Preparing for a clinical licence deal in Japan’ has been published.
Please contact or connect with Regeneus via social media platforms below if you’d like further information.
To view the Edison Report, please visit: http://abnnewswire.net/lnk/ZT58EC4E
WEB: Edison Investment Report Issued
About: Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.
